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Abstract
Digenic Connexin26 (Cx26, GJB2) and Cx30 (GJB6) heterozygous mutations are the second most 
frequent cause of recessive deafness in humans. However, the underlying deafness mechanism 
remains unclear. In this study, we created different double Cx26 and Cx30 heterozygous (Cx26+/−/
Cx30+/−) mouse models to investigate the underlying pathological changes and deafness 
mechanism. We found that double Cx26+/−/Cx30+/− heterozygous mice had hearing loss. 
Endocochlear potential (EP), which is a driving force for hair cells producing auditory receptor 
current, was reduced. However, unlike Cx26 homozygous knockout (Cx26−/−) mice, the cochlea in 
Cx26+/−/Cx30+/− mice displayed normal development and had no apparent hair cell degeneration. 
Gap junctions (GJs) in the cochlea form two independent networks: the epithelial cell GJ network 
in the organ of Corti and the connective tissue GJ network in the cochlear lateral wall. We further 
found that double heterozygous deletion of Cx26 and Cx30 in the epithelial cells did not reduce 
EP and had normal hearing, suggesting that Cx26+/−/Cx30+/− may mainly impair gap junctional 
functions in the cochlear lateral wall and lead to EP reduction and hearing loss. Most of Cx26 and 
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Cx30 in the cochlear lateral wall co-expressed in the same gap junctional plaques. Moreover, sole 
Cx26+/− or Cx30+/− heterozygous mice had no hearing loss. These data further suggest that 
digenic Cx26 and Cx30 mutations may impair heterozygous coupling of Cx26 and Cx30 in the 
cochlear lateral wall to reduce EP, thereby leading to hearing loss.
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Introduction
Gap junction (GJ) connexin gene mutations induce high incidence of nonsyndromic hearing 
loss. Connexin26 (Cx26, GJB2) and Cx30 (GJB6) are two major deafness genes and 
predominantly express in the cochlea [1]. Either Cx26 or Cx30 mutations can induce hearing 
loss [1–3]. However, digenic heterozygous mutations for Cx26 and Cx30 are also often 
found clinically and are the second most frequent cause of nonsyndromic hearing loss in 
different human populations [4–16]. The phenotypes in these patients heterozygous for Cx26 
and Cx30 mutations are various; hearing loss can be either prelingual or postlingual, ranging 
from mild or moderate to severe or profound deafness [2,11,14, 17,18].
GJs exist extensively in the inner ear, including the spiral limbus, supporting cells in the 
organ of Corti, and the cochlear lateral wall, and form two independent networks: epithelial 
cell network in the cochlear epithelium and connective tissue network in the cochlear lateral 
wall (Fig. 1f). However, there is no GJ and connexin expression in auditory sensory hair 
cells [19–22]. Cx26 and Cx30 are predominant isoforms in the cochlea [23]. Cx26 and Cx30 
in the cochlea have overlapping distributions [19,21,24–26] and can form functional 
heterotypic/heteromeric (hybrid) GJ channels [27], which possess a rectified transjunctional 
gating and can induce a directional passage [27,28].
Mouse models show that Cx26 deletion can induce deafness [1]. Cx26 deficient mice show 
cochlear developmental disorders, hair cell degeneration, endocochlear potential (EP) 
reduction, and active cochlear amplification reduction [1]. In the clinic, Cx26 mutation 
induced hearing loss can be divided into two groups, congenital deafness and late-onset 
hearing loss. Congenital deafness induced by Cx26 deficiency mainly results from cochlear 
developmental disorders, whereas progressive, late-onset hearing loss induced by Cx26 
deficiency is associated with the reduction of cochlear active amplification [1, 30–35]. 
However, the hypothesized K+-recycling impairment is not a primary deafness mechanism 
for Cx26 deficiency-induced hearing loss [36].
Previous Cx30 knockout (KO) mice also showed hearing loss [29,30]. However, it has been 
found that Cx26 expression in this Cx30 KO mouse line is also reduced [37]. A recent 
experiment showed that a Cx30 KO mouse created by Cre-FloxP technique have no hearing 
loss until 2-month old [38].
It has been reported in brief that double Cx26 and Cx30 heterozygous deficient mice have 
hearing loss [39]. However, the detailed pathological changes remain unclear; the underlying 
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deafness mechanism also remains undetermined. In this study, the detailed underlying 
pathological changes in the cochlea were investigated. We also created different mouse 
models to investigate the mechanisms underlying digenic heterozygous deficiency of Cx26 
and Cx30 induced hearing loss. We found that double Cx26 and Cx30 heterozygous 
(Cx26+/−/Cx30+/−) mice have hearing loss, which mainly results from EP reduction likely 
caused by impairment of GJ heterotypic coupling function in the cochlear lateral wall.
Materials and Methods
Double Cx26 and Cx30 heterozygous KO mouse generation and genotyping
Two lines of double Cx26 and Cx30 heterozygous (Cx26+/−/Cx30+/−) mice were generated 
by different Cx26 conditional KO (cKO) mice crossing with Cx30 KO mice. In the first line, 
Cx26 cKO mice were generated by crossing Cx26loxP/loxP mice (EM00245, European 
Mouse Mutant Archive) with the Pax2-Cre mouse line (the Mutation Mouse Regional 
Center, Chapel Hill, NC) [31]. Then, Cx26 cKO mice were further crossed with Cx30 KO 
mice (EM00323, European Mouse Mutant Archive) [30] to create Cx26 and Cx30 
heterozygous (Cx26+/−/Cx30+/−) mice. The Cx26 floxed allele and Pax2-Cre transgene were 
detected on tail genomic DNA by PCR amplification using the following primers: Cx26F: 
5′-CTT TCC AAT GCT GGT GGA GTG-3′ and Cx26R: 5′-ACA GAA ATG TGT TGG 
TGA TGG-3′ for the Cx26 floxed allele; Pax2-CreF: 5′-GCC TGC ATT ACC GGT CGA 
TGC AAC GA- 3′ and Pax2-CreR: 5′-GTG GCA GAT GGC GCG GCA ACA CCA TT- 3′ 
for Pax2-Cre transgene. Cx26loxP/loxP and WT mice generated 400 and 300 bps bands, 
respectively. The band of Pax2-Cre was 700 bps. Primer pairs for detecting Cx30 KO were 
Cx30 KO-1 (LACZ e Neo): 5′-GGT ACC TTC TAC TAA TTA GCT TGG -3′; Cx30 KO2 
(LACZ e Neo): 5′-AGG TGG TAC CCA TTG TAG AGG AAG -3′; Cx30 KO-3 (LACZ e 
Neo) 5′-AGC GAG TAA CAA CCC GTC GGA TTC -3′. The bands of Cx30 KO and WT 
mice are located at 460 and 544 bps, respectively.
The second Cx26+/−/Cx30+/− mouse line was created by crossing Prox1-CreERT2 mouse 
line (Stack No. 022075, The Jackson Lab) with Cx26loxP/loxP transgenic mice to create 
Tamoxifen-inducible Prox1-Cx26 cKO mice [32]. After intraperitoneal injection with 
Tamoxifen (T5648, Sigma-Aldrich, St. Louis, MO) with 0.5 mg/10g per day for three days 
after birth, Cx26 expression in Deiters cells (DCs) and outer pillar cells (OPCs) in the 
cochlear epithelial cell GJ network is selectively deleted [32]. Then, Prox1-Cx26 cKO mice 
were further crossed with Cx30 KO mice to establish double Prox1-Cx26+/−/Cx30+/− 
heterozygous mice. WT littermates were used as controls. All experimental procedures were 
conducted in accordance with the policies of the University of Kentucky Animal Care & Use 
Committee.
Auditory brainstem response and distortion product otoacoustic emission measurements
As we previously reported [30–33], mice were anesthetized by intraperitoneal injection with 
a mixture of Ketamine and Xylazine (a stock solution: 8.5 ml saline+1 ml Ketamine+0.55 ml 
Xylazine) given at a dose of 0.1 ml/10 g body weight. Body temperature was maintained at 
37–38°C by placing anesthetized mice on an isothermal pad (Deltaphase, model 39dp, 
Braintree Scientific Inc., Massachusetts). Auditory brainstem response (ABR) and distortion 
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product otoacoustic emission (DPOAE) were recorded in a double-wall sound isolated 
chamber by use of a Tucker-Davis ABR workstation (Tucker-Davis Tech. Alachua, FL). 
ABR was evoked by both clicks and series of tone bursts (4 – 40 kHz, 10–80 dB SPL, a 
5dB-step) with an ES-1 high-frequency speaker (Tucker-Davis Tech. Alachua, FL). The 
ABR threshold was determined by the lowest level at which an ABR can be recognized. If 
mice had severe hearing loss, the ABR test at the intensity range of 70 – 110 dB SPL was 
used.
For DPOAE recording, two plastic tubes were inserted into the external ear canal and sealed 
with an earplug. Two pure tones (f1 and f2, f2/f1 =1.22) were simultaneously delivered into 
the ear. The test frequencies were presented by a geometric mean of f1 and f2 [f0 = (f1 × 
f2)1/2]. The intensity of f1 (I1) was set at 5 dB SPL higher than that of f2 (I2). The responses 
were averaged by 150 times [32,33].
Endocochlear potential recording
As we previously reported [30,32,40], mice were anaesthetized as described above and the 
body temperature was maintained at 37–38 °C. The trachea was exposed and cut along the 
middle line. The tracheal tube was put into the trachea. Then, the cochlea was exposed by a 
ventral approach and the bone over the spiral ligament was gently picked to form a small 
hole. A glass pipette filled with a K+-based intracellular solution [41] was inserted into the 
hole. The DC potential was continually recorded as the electrode pipette penetrated through 
the lateral wall by use of MultiClamp 700A amplifier (Molecular Devices, CA) and digitized 
utilizing a Digidata 1322A (Molecular Devices, CA).
Immunofluorescent staining
The cochlear tissue preparation and immunofluorescent staining were performed as we 
previously described [21,26]. The cochlear cross-sections were fixed with 4% 
paraformaldehyde in 0.1 M PBS (pH 7.4) for 30 min. After being washed with PBS (0.1 M) 
3 times, the tissue was incubated in a blocking solution (10% goat serum and 1% BSA in the 
PBS) with 0.1% Triton X-100 for 30 min at room temperature. The tissue then was 
incubated with primary antibody in the blocking solution at 4°C overnight. Monoclonal 
mouse anti-Cx26 (Cat# 33-5800) and polyclonal rabbit anti-Cx30 (Cat#71-2200, Invitrogen 
Corp, Carlsbad, CA) were used. After completely washing out the primary antibodies with 
PBS, the reaction to a 1:600 dilution of secondary Alexa Fluor® 488 or 568 conjugated 
antibodies (Molecular Probes) in the blocking solution followed at room temperature for 1 
hr. After completely washing out, the section was mounted with a fluorescence mounting 
medium (H-1000, Vector Lab, CA) and observed under a Leica confocal microscope (Leica 
TCS SP2) or a fluorescence microscope (Nickon T2000).
For quantitative measure of Cx26 and Cx30 expression, the labeled pixels and intensity in 
the organ of Corti and the cochlear lateral wall were accounted and measured by use of 
ImageJ software (NIH, Bethesda, USA) [21,33]. The average of labeling intensity was 
calculated after subtraction of background intensity. Then, the averaged labeling intensities 
were normalized to those in WT mice.
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Data processing and statistical analysis
Data were plotted by SigmaPlot and statistically analyzed by SPSS v18.0 (SPSS Inc. 
Chicago, IL). Error bars represent s.e.m. and data were expressed as mean ± s.e.m. other 
than indicated in text.
Results
Hearing loss in double Cx26+/−/Cx30+/− heterozygous mice
Fig. 1 shows Cx26 and Cx30 expression in the cochlea in Cx26+/−/Cx30+/− heterozygous 
mice. Fluorescent staining shows that expression of Cx26 and Cx30 in the cochlea is visible 
in Cx26+/−/Cx30+/− heterozygous mice (Fig. 1c&d). However, in comparison with that in 
WT mice (Fig. 1a&b), the intensity of staining appears weaker. Quantitative measure shows 
that intensities of Cx26 and Cx30 labeling in the organ of Corti and cochlear lateral wall in 
Cx26+/−/Cx30+/− heterozygous mice were reduced by ~ 50% (Fig. 1e). The normalized 
intensities of Cx26 and Cx30 labeling in Cx26+/−/Cx30+/− mice were 50.9±3.8% and 
53.7±3.2%, respectively, in the organ of Corti and 53.4±6.4% and 52.7±5.4%, respectively, 
in the cochlear lateral wall.
ABR recording shows that double Cx26+/−/Cx30+/− heterozygous mice had hearing loss 
(Fig. 2). The ABR threshold in double Cx26+/−/Cx30+/− heterozygous mice was 46.4±1.26 
dB SPL for click stimulations and was significantly increased in comparison with the ABR 
threshold (29.5±0.56 dB SPL) in littermate WT controls (P<0.001, one-way ANOVA with a 
Bonferroni correction). The hearing loss occurred in whole-frequency range (Fig. 2c). The 
ABR thresholds in 8–40 kHz range were increased to 45–70 dB SPL. In comparison with 
Cx26−/− mice and Cx30−/− mice, which demonstrated complete deafness (ABR thresholds 
>100 dB SPL, Fig. 2a&b), hearing loss in double Cx26+/−/Cx30+/− heterozygous mice was 
mild to moderate. However, single Cx26+/− or Cx30+/− heterozygous mice had no hearing 
loss. The ABR thresholds for click stimulation in sole Cx26+/− mice or Cx30+/− mice were 
30.2±0.61 and 30.1±0.75 dB SPL, respectively, similar to that (29.5±0.56 dB SPL) in WT 
mice (Fig. 2b).
Reduction of DPOAE in Cx26+/−/Cx30+/− mice
DPOAE in Cx26+/−/Cx30+/− mice was also reduced (Fig. 3). The DPOAE thresholds in 
Cx26+/−/Cx30+/− mice at 8, 16, and 20 kHz were 38.8±1.30, 30.6±0.95, and 43.4±1.13 dB 
SPL, respectively (Fig. 3b). In comparison with WT mice, the threshold of DPOAE in 
Cx26+/−/Cx30+/− mice were significantly increased by 5- 10 dB SPL (P>0.001, one-way 
ANOVA with a Bonferroni correction).
Normal cochlear development and no cell degeneration in Cx26+/−/Cx30+/− mice
Cx26 cKO mice with deletion of Cx26 at birth have cochlear developmental disorders and 
severe hair cell degeneration [31,35,42]. However, double Cx26+/−/Cx30+/− heterozygous 
mice had no cochlear developmental disorders (Fig. 4a&b). The cochlea showed normal 
shape and the cochlear tunnel is open. Also, there was no apparent cell degeneration in 
Cx26+/−/Cx30+/− mice (Fig. 4). Hair cells also had no apparent loss (Fig. 4c&d).
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No hearing loss in double Prox1-Cx26+/−/Cx30+/− heterozygous mice
As shown in Fig. 1f, gap junctions in the cochlea form two GJ networks. We previously 
reported that Prox1-Cx26 cKO mice [32,33] have selective deletion of Cx26 expression in 
the Deiters cells (DCs) and outer pillar cells (OPCs) in the epithelial cell GJ network (Fig. 
5a&b). In this experiment, we further crossed Prox1-Cx26−/− mice with Cx30−/− mice to 
establish double Prox1-Cx26+/−/Cx30+/− heterozygous mice (Fig. 5). In this Prox1-Cx26+/−/
Cx30+/− mouse, only DCs and OPCs in the epithelial cell GJ network were double 
heterozygous for Cx26 and Cx30. Intensity of labeling for Cx26 and Cx30 in the organ of 
Corti was reduced almost by half (0.555±0.063 and 0.549±0.053, respectively) in 
comparison with those in WT littermate mice. However, in the lateral wall, only Cx30 
labeling was reduced by half (0.517±0.079), whereas the expression of Cx26 appeared as the 
same (0.939±0.054) as that in WT mice (Fig. 5c&d). There is no significant difference 
between them (P=0.289, one-way ANOVA).
Unlike Cx26+/−/Cx30+/− mice that have hearing loss (Fig. 2), Prox1-Cx26+/−/Cx30+/− mice 
had no hearing loss as measured by ABR threshold (Fig. 6). In comparison with WT 
littermate mice, there were no significant difference in ABR thresholds between two groups 
(P=0.53, one-way ANOVA).
EP reduction in Cx26+/−/Cx30+/− mice but not in Prox1-Cx26+/−/Cx30+/− mice
EP is a driving force required for hair cells generating auditory receptor current and potential 
and is required for hearing. We found that EP in WT and Cx26+/−/Cx30+/− mice was 
98.2±1.41 and 55.7±5.14 mV, respectively (Fig. 7a); EP in Cx26+/−/Cx30+/− mice was 
significantly reduced (P<0.001, one-way ANOVA with a Bonferroni correction). However, 
EP in Prox1-Cx26+/−/Cx30+/− mice was 92.6±6.59 mV and was not significantly changed in 
comparison with EP in WT littermate mice (91.1±4.51 mV, P=0.42, one-way ANOVA). On 
the other hand, EP in Cx26 homozygous KO mice and Cx30 homozygous KO mice were 
dramatically reduced to 62.8±6.25 and 2.98±1.62 mV, respectively (Fig. 7b). Positive EP in 
Cx30 KO mice was almost abolished.
EP generation and heterozygous gap junctional coupling in the cochlear lateral wall
Positive EP is generated in the cochlear lateral wall. Based on a widely-accepted “two-cell 
model” [43–45], EP is generated by marginal cells (cell 1) and the intermediate cells 
coupled with the basal cells in the stria vascularis and neighboring fibrocytes in the spiral 
ligament by GJs (cell 2) (Fig. 9). Cx26 and Cx30 are predominant connexin isoforms in the 
cochlear lateral wall [24–26]. Fig. 8 shows that expression of Cx26 and Cx30 overlapped in 
most cells in the cochlear lateral wall. In particular, most of Cx26 and Cx30 co-located at the 
same punctate but at different sides (indicated by empty triangles in Fig. 8b and white error 
heads in Fig. 8c), indicating that Cx26 and Cx30 may form heterotypic gap junctional 
channels as previously reported in the cochlear supporting cells in the cochlear sensory 
epithelium [21,27].
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Discussion
In this study, we investigated the deafness mechanism underlying digenic Cx26 and Cx30 
heterozygous mutations by creating double Cx26+/−/Cx30+/− heterozygous deficient mice. 
We found that double Cx26+/−/Cx30+/− heterozygous mice had hearing loss (Fig. 1). The 
ABR and DPOAE thresholds were increased (Figs. 2&3). The cochlea displayed normal 
development and had no apparent hair cell loss (Fig. 4). EP in Cx26+/−/Cx30+/− mice was 
reduced (Fig. 7). These data are consistent with a previous report that double Cx26 and 
Cx30 heterozygous mice had EP reduction and hearing loss [39].
The positive EP is generated in the cochlear lateral wall. As mentioned above, the cochlear 
gap junctions form two independent networks (Fig. 1f): epithelium GJ network in the 
cochlear epithelium and connective tissue GJ network in the cochlear lateral wall. In this 
study, we further created Prox1-Cx26+/−/Cx30+/− mice, in which Cx26 expression only in 
DCs and OPCs in the epithelial cell GJ network was selectively reduced [32,33]. Prox1-
Cx26+/−/Cx30+/− mice displayed normal hearing (Fig. 6) and normal EP (Fig. 7a). These 
data further suggest that Cx26+/−/Cx30+/− may mainly impair connective tissue GJ network 
function in the cochlear lateral wall leading to EP reduction and hearing loss, similar to our 
previous finding that the reduction of EP by deletion of Panx1 reducing ATP release induces 
hearing loss [40].
Positive EP is a driving force for hair cells producing auditory receptor current and is 
required for hearing. As described by two-cell model for EP generation [40,45], fibrocyte 
cells in the spiral ligament are depolarized to approximately -5 mV by coordination of ATP-
dependent Kir5.1 K+ channels, Na+, K+-ATPases, and Na+, K+, 2Cl− cotransporters, which 
consequently leads to depolarization of the intermediate cells in the stria vascularis to ~ −5 
mV through gap junctional coupling (Fig. 9). Due to low K+ concentration (1–2 mM) in the 
intrastrial space (IS), ATP-dependent Kir4.1 K+ channels located at the apical membrane of 
the intermediate cells further generate 105–110 mV transmembrane potential between the 
intracellular space and the intrastrial space. Thus, with respect to normal extracellular space, 
the intrastrial space becomes positive 110–115 mV. This positive potential eventually leads 
to positive EP (+100–110 mV) in the endolymph in the scala media [40,45]. Apparently, gap 
junctional coupling plays a critical role in EP generation (Fig. 9). Also, K+-flowing from the 
fibrocytes to the intermediate cells to the intrastrial space is following a K+-ion 
concentration gradient but against the voltage gradient (moving cationic ions from negative 
voltage to positive voltage). Thus, the rectified gating between basal cells and intermediate 
cells or between the fibrocytes and the basal cells may be required for the directional 
passage of K+-ions and the efflux of K+-ions to the intrastrial space (Fig. 9), just like 
rectified-outward K+-channels acting in the efflux of K+-ions after cell depolarization. 
Moreover, both Cx26 and Cx30 deletion can reduce EP (Fig. 7b). This indicates that either 
Cx26 or Cx30 deletion cannot be compensated by each other for EP generation, i.e., Cx26/
Cx30 heterotypic channels are required for the EP generation.
Indeed, Cx26 and Cx30 can form heterotypic gap junctional channels both in vitro [46] and 
in vivo, which possess a rectified gating property [27] and can induce a directional voltage 
gradient and passage [28]. In this experiment (Fig. 8a–c) and also in our previous study [26], 
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we found that most of Cx26 and Cx30 in the cochlear lateral wall co-localize at the same GJ 
plaque, which may be able to assemble to functional heterotypic gap junctional channels 
[25,27]. Digenic Cx26 and Cx30 mutations may compromise heterotypic gap junctional 
function in the cochlear lateral wall, thereby leading to EP reduction and hearing loss. 
Indeed, it has been found that some Cx26 deafness-associated mutants, such as p.V84L and 
p.V95M, can form functional homotypic gap junctional channels but cannot form functional 
heterotypic channels [47–50], indicating that these Cx26 mutants may specifically impair 
heterotypic channel function in vivo. The current study may also provide a deafness 
mechanism underlying these Cx26 mutants. In this experiment, we found that Cx26 and 
Cx30 expression in Cx26+/−/Cx30+/− heterozygous mice reduced but not completely 
abolished (Fig. 1). Moreover, sole Cx26+/− heterozygous or Cx30+/− heterozygous mice have 
no hearing loss (Fig. 2b). These data further suggest that digenic Cx26 and Cx30 mutations 
may mainly impair heterotypic GJ channel function leading to hearing loss.
In the clinic, the most common genotype for digenic Cx26 and Cx30 deafness mutations is 
Cx30 truncate deafness mutations (GJB6-D13S1830 and GJB6-D13S1854) with either 
homozygous, or heterozygous in trans with recessive Cx26 (GJB2) mutations [2,3]. It has 
been reported the existence of a distance cis-regulatory region that controls both Cx26 and 
Cx30 expression [18,51–53]. The truncate deletion may involve this co-regulatory element 
(region) and prevents the expression in cis of the normal GJB2 gene. If co-existence of GJB2 
(Cx26) mutations in trans, this can lead to the complete absence of Cx26 expression and 
function. Indeed, it has been reported that Cx26 and Cx30 expressions in mutated GJB2 
allele in trans with large deletion in Cx30 (GJB6-D13S1830 and GJB6-D13S1854) 
dramatically reduced or abolished Cx26 expression at the transcription level [18,52,53]. 
However, the further pathological changes and the underlying deafness mechanism still 
remain unclear. Recently, we found that Cx26 deficiency can disrupt miRNA intercellular 
transfer in the cochlea and cause cochlear developmental disorders, thereby leading to 
deafness [35,54]. It has been reported that expression of Cx26 in the Cx30 KO mice and 
Cx30 T5M deafness mutant knockin mice is also reduced, which may lead to hearing loss 
[37,55]. As mentioned above, Cx26 deficiency can induce cochlear developmental disorders 
and hair cell degeneration [31,35]. However, Cx26+/−/Cx30+/− heterozygous mice have 
neither cochlear developmental disorders nor severe hair cell degeneration (Fig. 4). Thus, 
hearing loss in Cx26+/−/Cx30+/− heterozygous mice does not solely result from the reduction 
of Cx26 expression.
In this study, we found that EP reduction is a determining factor for hearing loss in double 
Cx26+/−/Cx30+/− heterozygous mice (Fig. 7). EP was also reduced or abolished in Cx26 KO 
or Cx30 KO mice (Fig. 7b, also see [29,30,56]). However, we previously found that EP 
reduction and hair cell degeneration are not primary causes for Cx26 deletion induced 
congenital deafness [30,31]; EP reduction is also not associated with Cx26 deficiency 
induced progressive, late-onset hearing loss [34]. These data further indicate that unlike 
monogenic Cx26 or Cx30 mutations, heterozygous Cx26/Cx30 mutations have different 
underlying mechanisms for deafness and may be associated with impairment in Cx26/30 
heterotypic channel function, which need to be further studied in future.
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Our recent experiments also demonstrated that the hypothesized impairment of K+-recycling 
in the cochlea is not a mechanism for Cx26 deficiency induced hearing loss [1,34,36]. The 
hypothesis of K+-recycling impairment proposes that cochlear GJs will be impaired due to 
Cx26 or Cx30 deficiency and causes K+-recycling in the cochlea impaired, which 
consequently causes K+-ions accumulated in the extracellular space around hair cells and 
eventually leads to hair cell degeneration and hearing loss. In this experiment, double 
Cx26+/−/Cx30+/− heterozygous mice displayed normal cochlear development and had no 
hair cell loss (Fig. 4). These data provide further evidence that the K+-recycling hypothesis 
is not a mechanism for Cx26 and Cx30 deficiency induced hearing loss.
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Highlights
• Digenic Cx26 and Cx30 mutation is the 2nd cause for recessive deafness in 
humans
• Double Cx26+/−/Cx30+/− heterozygous mice have hearing loss
• There is EP reduction but no hair cell loss in Cx26+/−/Cx30+/− mice
• Sole Cx26+/− or Cx30+/− heterozygous mice have no hearing loss
• Hearing loss may result from heterotypic-GJ impairment in the cochlear 
lateral wall
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Fig. 1. 
Gap junction network in the cochlea and Cx26 and Cx30 expression in the Cx26+/−/Cx30+/− 
mouse cochlea. a–d: Immunofluorescent staining for Cx26 (green) and Cx30 (red) in the 
cochlea in Cx26+/−/Cx30+/− and WT mice. Both Cx26 and Cx30 labeling is visible in the 
Cx26+/−/Cx30+/− mouse cochlea but their intensities are weaker in comparison with those in 
WT mice. Scale bar: 50 μm. e: Quantitative measure of Cx26 and Cx30 labeling in the organ 
of Corti (OC) and the cochlear lateral wall (LW) in WT mice and Cx26+/−/Cx30−/+ mice. 
The intensity of labeling was normalized to the average value in WT mice. The expression 
of Cx26 and Cx30 in Cx26+/−/Cx30+/− mice was significantly reduced. **: P > 0.001, t-test. 
f: Schematic drawing of two gap junctional (GJ) networks in the cochlea: epithelial cell GJ 
(ECGJ) network in the cochlear sensory epithelium and connective tissue GJ (CTGJ) 
network in the cochlear lateral wall. Hair cells have neither gap junction nor connexin 
expression. SV, scala vestibuli; SM, scala media; ST, scala tympani.
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Fig. 2. 
Hearing loss in double Cx26 and Cx30 heterozygous (Cx26+/−/Cx30+/−) mice. a: ABRs 
were evoked by click stimulations in WT, Cx26+/−/Cx30+/−, Cx26+/−, Cx30+/−, Cx26−/−, and 
Cx30−/− mice. b: Hearing loss in Cx26+/−/Cx30+/−, Cx26−/−, and Cx30−/− mice. ABR 
thresholds evoked by click stimulations were increased in Cx26+/−/Cx30+/−, Cx26−/−, and 
Cx30−/− mice. c: ABR thresholds in Cx26+/−/Cx30+/− and WT mice evoked by tone bursts. 
Hearing loss was observed in the whole-tested frequency range in Cx26+/−/Cx30+/− mice. 
WT littermates served as control. Mice were 6–8 weeks old. **: P<0.001 as determined by 
one-way ANOVA with a Bonferroni correction.
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Fig. 3. 
Reduction of DPOAE in Cx26+/−/Cx30+/− mice. a: Spectrum of acoustic emission recorded 
from Cx26+/−/Cx30+/− and WT mice. Insets: Large scale plotting of 2f1−f2 and f1 peaks. The 
peak of DPOAE (2f1−f2) in Cx26+/−/Cx30+/− mice was reduced but f1 and f2 peaks remained 
the same as those in WT mice. f0=20 kHz, I1/I2=60/55 dB SPL. b: DPOAE thresholds in 
Cx26+/−/Cx30+/− mice were increased. WT littermates served as control. Data are expressed 
as mean ± S.D. **: P < 0.001 as determined by one-way ANOVA with a Bonferroni 
correction.
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Fig. 4. 
Normal development of the cochlea and no hair cell loss in Cx26+/−/Cx30+/− mice. a–b: 
Cross-sections of the Cx26+/−/Cx30+/− mouse cochlea. The cochlea demonstrates normal 
shape and has no apparent cell degeneration. SV, scala vestibuli; SM, scala media; ST, scala 
tympani. c–d: whole-mounting of the cochlear sensory epithelium in Cx26+/−/Cx30+/− mice. 
Inner hair cells (IHCs) and outer hair cells (OHCs) were stained with phalloidin-Alexa 488 
(green) and the cell nuclei were labeled with propidium iodide (PI, red). Mice were 2–3 
months old. Scale bar: 100 μm in a & c, 40 μm in b, and 20 μm in d.
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Fig. 5. 
Connexin expression in Prox1-Cx26+/−/Cx30+/− mice. a: Double immunofluorescent 
staining for Cx26 and Cx30 in Prox1-Cx26+/−/Cx30+/− mice. b: Schematic drawing shows 
target-deletion of Cx26 in Deiters cells (DCs) and outer pillar cells (OPCs) in the cochlear 
sensory epithelium in Prox1-Cx26 KO mice. c–d: Quantitative measure of Cx26 and Cx30 
labeling in the organ of Corti (OC) and the cochlear lateral wall (LW) in WT mice and 
Prox1-Cx26+/−/Cx30−/+ mice. Littermates were used as controls. The intensity of labeling 
was normalized to the average value in WT mice. The expression of Cx26 and Cx30 in the 
OC in Prox1-Cx26+/−/Cx30+/− mice was significantly reduced. However, the expression of 
Cx26 in the lateral wall was not reduced. **: P > 0.001, t-test.
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Fig. 6. 
No hearing loss in Prox1-Cx26+/−/Cx30+/− mice. WT littermates served as control. Mice 
were 4–8 weeks old. Data are expressed as mean ± S.D.
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Fig. 7. 
EP reduction in Cx26+/−/Cx30+/− mice but not in Prox1- Cx26+/−/Cx30+/− mice. a. The EP 
was significantly reduced in Cx26+/−/Cx30+/− mice but not in Prox1- Cx26+/−/Cx30+/− mice. 
WT littermates served as control. **: P < 0.001 as determined by one-way ANOVA with a 
Bonferroni correction. b. EP reduction in homozygous Cx26−/− KO mice and homozygous 
Cx30−/− KO mice. Mice were 4–8 weeks old.
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Fig. 8. 
Co-expression of Cx26 and Cx30 and EP generation in the cochlear lateral wall. The cross-
section of the mouse cochlear lateral wall was stained for Cx26 (green) and Cx30 (red) in 
immunofluorescent staining. Empty triangles in panel b indicate heterozygous coupling 
between stria vascularis (basal cell layer) and spiral ligament (fibrocyte I cells). White errors 
in panel c indicate co-labeling of Cx26 and Cx30 at the same GJ plaques between fibrocyte 
cells in the spiral ligament. Most of GJ plaque-punctates have Cx26 and Cx30 co-labeling 
and show yellow color in the over-lap image. St. V, stria vascularis; SPL, spiral ligament. 
Scale bar: 20 μm in a & b and 10 μm in c.
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Fig. 9. 
Schematic drawing of EP generation in the cochlear lateral wall. Based on the “two-cell” 
model, EP is generated by Kir4.1 in the apical membrane of intermediate cells in 
conjunction with Kir5.1 channels, Na+/K+ ATPases, and Na+, K+, 2Cl−-cotransporters in the 
fibrocytes through GJ coupling [40,45]. Heterozygous couplings of gap junctions between 
fibrocute I and II cells in the spiral ligament (SPL), between fibrocyte I cells and base cells 
in the stria vascularis (St. V), and between base cells and intermediate cells are important for 
eventually positive EP generation. MC: marginal cell; BC: basal cell; FC: fibrocyte; IC: 
intermediate cell; IS: intrastrial space; GJ: gap junction.
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